What does aducanumab treatment of Alzheimer's disease mean for research on vascular cognitive disorders?

Anders Wallin; Suvarna Alladi; Sandra E Black; Christopher Chen; Steven M Greenberg; Deborah Gustafson; Jeremy D Isaacs; Hanna Jokinen; Raj Kalaria; Vincent Mok; Leonardo Pantoni; Florence Pasquier; Gustavo C Roman; Gary A Rosenberg; Reinhold Schmidt; Eric E Smith; Atticus H Hainsworth

doi:10.1016/j.cccb.2022.100044

What does aducanumab treatment of Alzheimer's disease mean for research on vascular cognitive disorders?

Cereb Circ Cogn Behav. 2022 Feb 11:3:100044. doi: 10.1016/j.cccb.2022.100044. eCollection 2022.

Authors

Anders Wallin¹, Suvarna Alladi², Sandra E Black³, Christopher Chen⁴, Steven M Greenberg⁵, Deborah Gustafson⁶, Jeremy D Isaacs⁷, Hanna Jokinen⁸, Raj Kalaria⁹, Vincent Mok¹⁰, Leonardo Pantoni¹¹, Florence Pasquier¹², Gustavo C Roman¹³, Gary A Rosenberg¹⁴, Reinhold Schmidt¹⁵, Eric E Smith¹⁶, Atticus H Hainsworth¹⁷

Affiliations

¹ Institute of Neuroscience and Physiology, University of Gothenburg; and Memory Clinic, Sahlgrenska, University Hospital, Gothenburg, Sweden.
² National Institute of Mental Health and Neurosciences, Bangalore, India.
³ Department of Medicine (Neurology), Sunnybrook Health Sciences Centre and University of Toronto, Toronto, ON, Canada.
⁴ Memory Aging and Cognition Centre, Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
⁵ Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
⁶ Department of Neurology, State University of New York Downstate Health Sciences University, Brooklyn, New York, USA.
⁷ St George's University Hospitals NHS Foundation Trust, London, UK.
⁸ Division of Neuropsychology, HUS Neurocenter, Helsinki University Hospital and University of Helsinki; and Department of Psychology and Logopedics, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
⁹ Institute of Neuroscience Newcastle University, Campus for Ageing and Vitality, Newcastle upon Tyne, UK.
¹⁰ Lui Che Woo Institute of Innovative Medicine,Lui Che Woo Institute of Innovative Medicine, Gerald Choa Neuroscience Centre, Division of Neurology, Department of Medicine and Therapeutics, Prince of Wales Hospital, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.
¹¹ Stroke and Dementia Lab, Luigi Sacco Department of Biomedical and Clinical Sciences, University of Milan, Italy.
¹² Univ Lille, Inserm 1172, CHU Lille, Labex DistALZ, Licend 59000 Lille, France.
¹³ Methodist Neurological Institute, Houston, Texas 77030, USA.
¹⁴ Center for Memory and Aging, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.
¹⁵ Department of Neurology, Medical University Graz, Graz, Austria.
¹⁶ Cumming School of Medicine, University of Calgary, Calgary, Canada.
¹⁷ Molecular and Clinical Sciences Research Centre, St George's University of London, Mailpoint J-0B, Cranmer Terrace, London SW17 0RE, UK.

Abstract

•Controversial registration of aducanumab for Alzheimer's Disease•Aducanumab is the subject of post-licensing observational studies aiming to follow the effects of the drug•Given the high prevalence of cerebrovascular pathology it is important that these studies do not ignore vascular cognitive disorders•The studies may give detailed phenotyping data that may lead to knowledge of targets for treatments of patients with vascular cognitive disorders.

Publication types

Editorial

Abstract

Publication types

Grants and funding